


1. (Amended) A substituted 4-, 5-, 6-, or 7-indole or indoline derivative of Formula

wherein W is C, CH or COH and the dotted lines indicate optional bonds and

wherein A is a group having the formula




wherein X is CR^{1A}, CHR^{1A}, N, NR^{1B}, O, or S, where R^{1A} is as defined for R³ to R⁹ below, and where R^{1B} is as defined for R¹⁰ below;

Y is CR^{2A}, CHR^{2A}, N, NR^{2B}, O, or S, where R^{2A} is as defined for R³ to R⁹ below and where R^{2B} is as defined for R¹⁰ below, and

the dotted lines indicate optional bonds;

provided that X and Y are not both O or S;

A is a group having the formula




wherein X is CR^{1A}, CHR^{1A}, N, NR^{1B}, O, or S, where R^{1A} is as defined for R³ to

A⁴ R⁹ below, and where R^{1B} is as defined for R¹⁰ below;

U is C, CH, or N; and

the dotted lines indicate optional bonds; or

A is a group having the formula



wherein U is C, CH, or N;

Y is CR^{2A}, CHR^{2A}, N, NR^{2B}, O, or S, where R^{2A} is as defined for R³ to R⁹ below and where R^{2B} is as defined for R¹⁰ below; and

the dotted lines indicate optional bonds;

A4
n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5;

Z is CH₂, O, S, CO, SO, or SO₂, provided that if n is 0 then Z is CH₂;

R³-R⁹ and R¹¹ to R¹² are independently selected from hydrogen, halogen, cyano, nitro, C₁₋₆-alk(en/yn)yl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, hydroxy, hydroxy-C₁₋₆-alkyl, C₁₋₆ alkoxy carbonyl, C₃₋₈ cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, C₁₋₆ alkyl carbonyl, phenyl carbonyl, halogen substituted phenyl carbonyl, trifluoromethyl, trifluoromethylsulfonyloxy, C₁₋₆ alkylsulfonyl, aryl and hetero aryl, or two adjacent groups taken from R³ - R⁹ may together form a methylenedioxy group, or two adjacent groups R⁷ - R⁹ may together form a cyclopentyl or cyclohexyl ring which may be substituted with one or more methyl groups, or one of R³-R⁹ may alternatively be a group -NR¹³R¹⁴ wherein R¹³ is as defined for R¹⁰ below and R¹⁴ is hydrogen, C₁₋₆ alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆ alk(en/yn)yl, aryl, hetero aryl, aryl-C₁₋₆ alkyl, or hetero aryl-C₁₋₆ alkyl;

R¹⁰ is

- hydrogen, C₁₋₆ alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈ cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl, heteroaryl, aryl-C₁₋₆ alkyl, heteroaryl-C₁₋₆-alkyl, acyl, thioacyl, C₁₋₆-alkylsulfonyl, trifluoromethylsulfonyl; arylsulfonyl, or heteroarylsulfonyl;
- R¹⁵VCO- wherein V is O or S and R¹⁵ is C₁₋₆-alk(en/yn)yl, C₃₋₈ cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl, or heteroaryl; or
- a group R¹⁶R¹⁷NCO- or R¹⁶R¹⁷NCS- wherein R¹⁶ and R¹⁷ are independently selected from hydrogen, C₁₋₆ alk(en/yn)yl, C₃₋₈ cycloalk(en)yl, C₃₋₈ cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, heteroaryl, or aryl, or R¹⁶ and R¹⁷ together with the N-atom to which they are linked, form a pyrrolidinyl, piperidinyl, morpholinyl, or perhydroazepin group;

or an acid addition salt thereof.

AS 6. (Amended) A compound according to claim 1 wherein Z is CH₂ and n + m is 0, 1, 2, 3, 4, 5, or 6.

AS 11. (Amended) A compound of claim 1 wherein Z is CH₂ and n + m is 0, 1, 2, 3, 4, 5, or 6 and R³-R⁹ and R¹¹-R¹² is hydrogen, halogen, cyano, nitro, C₁₋₆-alkyl, C₁₋₆-alkoxy, hydroxy, hydroxy-C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl and trifluoromethyl; and R¹⁰ is hydrogen.

13. (Amended) A compound according to claim 1 which is

1-(2-(6-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-

tetrahydropyridine,

1-(2-(5-Fluoro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)-1,2,3,6-

tetrahydropyridine,

1-(3-(5-Fluoro-3-benzofuranyl)-1-propyl)-4-(1H-indol-4-yl)-1,2,3,6-

tetrahydropyridine,

1-(2-(6-Chloro-1H-indol-3-yl)-4-(1H-indol-4-yl)piperidine,

1-(2-(4-Chloro-1H-indol-3-yl)ethyl)-4-(1H-indol-4-yl)piperidine,

4-(1H-Indol-4-yl)-1-(2-(5-methyl-1H-indol-3-yl)ethyl)piperidine,

4-(1H-Indol-4-yl)-1-(2-(1H-indol-3-yl)ethyl)piperidine,

4-(1H-Indol-4-yl)-1-(3-(4-methyl-3-benzofuranyl)-1-propyl)piperidine,

or a pharmaceutically acceptable acid addition salt thereof.

14. (Amended) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

17. (Amended) A method for the treatment of a disorder or disease of a living animal body, which is responsive to the inhibition of serotonin reuptake and antagonism of 5-HT_{1A} receptors comprising administering to such a living animal

body, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.

A 8
18. (Amended) A method for the treatment of an affective disorder in a living animal body, comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable acid addition salt thereof.

Please add the following new claims.

19. (New) The method of claim 17 wherein said living animal body is a human.

20. (New) The method of claim 18 wherein said living animal body is a human.

A 9
21. (New) The method of claim 20 wherein said affective disorder is selected from the group consisting of depression, psychosis and anxiety disorder.

22. (New) The method of claim 20 wherein said affective disorder is an anxiety disorder selected from the group consisting of general anxiety disorder, panic disorder and obsessive compulsive disorder.